• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by WORK Medical Technology Group LTD

    1/5/26 8:00:35 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care
    Get the next $WOK alert in real time by email
    6-K 1 ea0271445-6k_work.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON D.C. 20549

     

    FORM 6-K 

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of January 2026

     

    Commission File Number: 001-42256

     

    WORK Medical Technology Group LTD

     

    Floor 23, No. 2 Tonghuinan Road

    Xiaoshan District, Hangzhou City, Zhejiang Province, The People’s Republic of China

     

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

     

    Form 20-F ☒            Form 40-F ☐ 

     

     

     

     

    Entry Into Material Definitive Agreements

     

    On December 30, 2025, WORK Medical Technology Group LTD (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with LWY GROUP LTD, a British Virgin Islands company and an existing shareholder of the Company, which is wholly owned by the Company’s chief operating officer, Baiming Yu (“LWY GROUP”). Pursuant to the Securities Purchase Agreement, LWY GROUP agreed to subscribe for and purchase from the Company, and the Company agreed to issue and sell to LWY GROUP, an aggregate of 100,000 Class B ordinary shares of the Company, par value US$5.00 per share, for an aggregate purchase price of $500,000, in accordance with Regulation S under the Securities Act of 1933, as amended.

     

    The closing of the transaction contemplated by the Securities Purchase Agreement is expected to take place on or about January 13, 2026. The entry into the Securities Purchase Agreement and the transaction contemplated thereby have been approved by both the Company’s audit committee of the board of directors and the board of directors.

     

    As a result of the above transaction, Baiming Yu, through LWY GROUP, will beneficially own 100,625 Class B ordinary shares of the Company, representing 2,012,500 votes on matters to be decided by way of a poll and approximately 54.96% of the aggregate voting power of the Company’s outstanding ordinary shares.

     

    The foregoing summary of the Securities Purchase Agreement is subject to, and qualified in its entirety by, such document. A copy of the Securities Purchase Agreement is attached hereto as Exhibits 10.1, and is incorporated herein by reference.

     

    1

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      WORK Medical Technology Group LTD
         
      By: /s/ Shuang Wu
      Name:  Shuang Wu
      Title: Chief Executive Officer

     

    Date: January 5, 2026

     

    2

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    10.1   Securities Purchase Agreement dated December 30, 2025 by and between WORK Medical Technology Group LTD and LWY GROUP LTD

     

    3

     

    Get the next $WOK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WOK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    WORK Medical Grants East China Exclusive Distribution Rights for AI-Automated Blood Cell Morphology Analyzer, Sets RMB10 Million Sales Target for 2026

    Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical", the "Company" or "we"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Medical Treatment Technology Co., Ltd. ("Hunan Saitumofei") has entered into a one-year exclusive distribution agreement (the "Agreement") with Shanghai Benke Medical Technology Co., Ltd. ("Shanghai Benke") to promote and distribute its newly launched AI-Automated Blood Cell Morphology Analyzer (CM-B600) (the "Analyzer") in East China throughout 2026. Th

    12/29/25 9:35:00 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    WORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval for Its AI-Automated Blood Cell Morphology Analyzer

    Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Co., Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence ("AI")-Automated Human Blood Cell Morphology Analyzer. This regulatory approval represents a milestone in WORK Medical's research and development strategy and is expected to position the Company's

    12/29/25 9:00:00 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025

    Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the "Reverse Stock Split"). The Company's Class A ordinary shares will begin trading on a post-split basis when the market opens on December 29, 2025. The Company's Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "WOK," with a new CUSIP number G9767H125. The Reverse

    12/24/25 11:30:00 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    $WOK
    SEC Filings

    View All

    SEC Form 6-K filed by WORK Medical Technology Group LTD

    6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

    2/9/26 9:55:09 PM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    SEC Form 20-F filed by WORK Medical Technology Group LTD

    20-F - WORK Medical Technology Group LTD (0001929783) (Filer)

    1/30/26 5:07:52 PM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by WORK Medical Technology Group LTD

    6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

    1/5/26 8:00:35 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care